Allogene Q2 Cash Tops $300 Million: A Strategic Inflection Point

Allogene Therapeutics reported Q2 2025 results with $302.6 million in cash and investments, a GAAP net loss of $50.9 million, and a projected cash runway into H2 2027. The company streamlined the ALPHA-three trial, advanced the ALLO-316 solid tumor program, and initiated the ALLO-329 autoimmune study. These developments signal critical strategic inflection points for its allogeneic CAR T cell pipeline, positioning Allogene as a leader in the nascent allogeneic CAR T solid tumor domain.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease, reported its second-quarter 2025 financial results and strategic advancements. The company announced a cash balance of $302.6 million, a GAAP net loss of $50.9 million, and a projected cash runway extending into the second half of 2027 [1].

Key highlights from the quarter include significant progress in the ALPHA3 trial, the initiation of the ALLO-329 autoimmune study, and the advancement of the ALLO-316 solid tumor program. The ALPHA3 trial, which is evaluating cemacabtagene ansegedleucel (Cema-Cel) in first-line consolidation in large B-cell lymphoma (LBCL), has been streamlined to proceed as a randomized study with two arms, comparing Cema-Cel after standard fludarabine and cyclophosphamide (FC) lymphodepletion to observation [1]. This trial is expected to provide MRD conversion rates between the two arms in the first half of 2026 [1].

The ALLO-329 study, which launched in the second quarter of 2025, is a Phase 1 RESOLUTION basket trial in rheumatology, evaluating CAR T therapy across multiple autoimmune conditions [1]. This trial features two lymphodepletion arms and aims to provide biomarker and proof-of-concept data in the first half of 2026 [1]. The ALLO-316 trial, which is the only allogeneic CAR T therapy to show potential in solid tumors, has completed enrollment in its Phase 1b cohort and presented updated data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [1]. The company has met with the FDA to align on the design of a pivotal trial for ALLO-316, laying the groundwork for potential partnership discussions [1].

Research and development expenses for the second quarter of 2025 totaled $40.2 million, while general and administrative expenses amounted to $14.3 million [1]. The company expects an expected decrease in cash, cash equivalents, and investments of approximately $150 million for 2025 and GAAP operating expenses of approximately $230 million, including estimated non-cash stock-based compensation expense of approximately $45 million [1].

Allogene Therapeutics will host a live conference call and webcast today at 2:00 p.m. PT / 5:00 p.m. ET to discuss financial results and provide a business update [1]. The listen-only webcast will be available on the Company's website at www.allogene.com under the Investors tab in the News and Events section [1].

References:
[1] Allogene Therapeutics, Inc. (2025). Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Strategic Advancements. Retrieved from https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-second-quarter-2025-financial